Basic Information
| Drug ID | DDPD06809 |
|
| Drug Name | Plerixafor | |
| Molecular Weight | 502.782 | |
| Molecular Formula | C28H54N8 | |
| CAS Number | 110078-46-1 | |
| SMILES | C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1 | |
| External Links | ||
| DRUGBANK | DB06809 | |
| PubChem Compound | 65015 | |
| PDR | 1190 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Melting Point | 131.5 | ℃ | 131.5 | ℃ | FDA label |
| pKa | 6.75 | - | 6.0-7.5 | - | MSDS |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| C Max | 0.24 | ng/mg | 0.24 | mg/kg | subcutaneous injection, SC; | DRUGBANK |
| T Max | 0.75 | h | 0.5-1 | h | subcutaneous injection, SC; | DRUGBANK |
| Clearance | 4.4 | L/h | 4.38 | L/h | Plasma clearance; | DRUGBANK | Clearance | 3.2 | L/h | 3.15 | L/h | Renal clearance; | DRUGBANK |
| Volume of Distribution | 0.30 | L/kg | 0.3 | L/kg | DRUGBANK | |
| Half-life | 4.4 | h | 4.4 | h | elimination half-life; Non-Hodgkin lymphoma; patients; | DRUGBANK | Half-life | 5.6 | h | 5.6 | h | elimination half-life; multiple myeloma; patients; | DRUGBANK | Half-life | 3.5 | h | 3.5 | h | elimination half-life; Hodgkin's lymphoma; | DRUGBANK | Half-life | 0.30 | h | 0.3 | h | distribution half-life; | DRUGBANK |
| Toxicity LD50 | 16.3 | mg/kg | 16.3 | mg/kg | subcutaneous injection, SC; mouse; | DRUGBANK | Toxicity LD50 | 50.0 | mg/kg | >50 | mg/kg | subcutaneous injection, SC; Rattus, Rat; | DRUGBANK | Toxicity LD50 | 5.2 | mg/kg | 5.2 | mg/kg | intravenous injection, IV; mouse; Rattus, Rat; | DRUGBANK |
| Protein Binding | 58.0 | % | 58 | % | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Frequency | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Max dose for adults | 0.24 | mg/kg | 0.24 | mg/kg | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR |
| Max dose for adults | 80.0 | mg/day | 20 | mg/dose | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR |
| Max dose for adults | 0.24 | mg/kg | 0.24 | mg/kg | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR |
| Max dose for adults | 160.0 | mg/day | 40 | mg/dose | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR |
| Max dose for geriatric | 0.24 | mg/kg | 0.24 | mg/kg | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR |
| Max dose for geriatric | 80.0 | 20 | mg/dose | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR | |
| Max dose for geriatric | 0.24 | mg/kg | 0.24 | mg/kg | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR |
| Max dose for geriatric | 160.0 | 40 | mg/dose | subcutaneous injection, SC | qid | Mozobil | plerixafor | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1